Suda (ASX: SUD) Approaches the World Health Organisation to Add ArTiMist to Its Guidelines

KEY TAKEAWAYS:

• SUDA Pharmaceuticals of Perth, Australia, announced on 7 May 2018, its intention to approach WHO for the inclusion of its spray ArTiMist in the guidelines for treatment of malaria.
• Subsequent to the Phase III trials of the product, it has proved to be more effective than quinine and quinidine, the conventional treatment options for severe malaria.
• The company’s decision to approach WHO was prompted by the potential licensee of the product and SUDA’s efforts are on to find out if any further information is required by WHO for including ArTiMist in its guidelines.

Australian pharmaceutical giant, SUDA (ASX: SUD), announced on 7 May 2018, its intention to persuade WHO for including ArTiMist to its list of guidelines concerning treatment plan for malaria among children. This decision of the Perth-based company comes in the wake of Phase III trials of the drug wherein it was proved as being superior to Quinine,
the conventional treatment option for malaria.

WHO recently released statistics wherein it revealed that mortality rate of severe malaria – particularly the cerebral version – had touched 100% and for this figure to fall to 10% levels, effective treatment plan and supportive care was a must. The WHO report also observed that in case of severe cases of malaria being admitted to a hospital/clinic, death occurred within a few hours of the patient having been admitted. In such a situation, the need of the hour was that of a highly effective anti-malarial drug as part of the therapy.

As per the current guidelines of WHO, antimalarial treatment comprises of two classes of medicines, the more widespread of which is quinine and quinidine. However, Phase III trial of ArTiMist proved that it was more effective than intravenous quinine in treating this medical condition.

SUDA’s decision to approach WHO to seek approval for ArTiMist was prompted by the potential licensee who would market it in future. Prior to approaching WHO, SUDA intends to find out if any additional data needs to be submitted for ArTiMist to be included in the guidelines.

About SUDA Pharmaceuticals (ASX: SUD)

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia.

Request Info